280 related articles for article (PubMed ID: 33078472)
21. Myelodysplastic/myeloproliferative neoplasms.
Foucar K
Am J Clin Pathol; 2009 Aug; 132(2):281-9. PubMed ID: 19605822
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.
Wesner N; Drevon L; Guedon A; Fraison JB; Terrier B; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Seksik P; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
Leuk Lymphoma; 2019 Jul; 60(7):1782-1788. PubMed ID: 30457024
[TBL] [Abstract][Full Text] [Related]
23. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
Wesner N; Drevon L; Guedon A; Fraison JB; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
Eur J Haematol; 2019 Jan; 102(1):63-69. PubMed ID: 30218579
[TBL] [Abstract][Full Text] [Related]
25. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.
Leguit RJ; Orazi A; Kucine N; Kvasnicka HM; Gianelli U; Arber DA; Porwit A; Ponzoni M
Virchows Arch; 2022 Oct; 481(4):621-646. PubMed ID: 35819517
[TBL] [Abstract][Full Text] [Related]
26. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
27. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
28. Thrombosis in myeloproliferative and myelodysplastic syndromes.
Landolfi R; Di Gennaro L
Hematology; 2012 Apr; 17 Suppl 1():S174-6. PubMed ID: 22507813
[TBL] [Abstract][Full Text] [Related]
29. Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.
Papo M; Friedrich C; Delaval L; Boysson H; Viallard JF; Bachmeyer C; Sené T; Humbert S; Duffau P; Contis A; Agard C; Gombert B; Puyade M; Foucher A; Alary AS; Danlos FX; Régent A; Mouthon L; Guillevin L; Samson M; Kosmider O; Terrier B;
Rheumatology (Oxford); 2022 Feb; 61(2):775-780. PubMed ID: 33836046
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
31. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
Smith BN; Savona M; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
[TBL] [Abstract][Full Text] [Related]
32. The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms.
d'Izarny-Gargas T; Isnard P; Boudhabhay I; Buob D; Moktefi A; Linster C; Hummel A; Esteve E; Audard V; Lazareth H; Maroun N; Hertig A; Gosset C; Jouzel C; Permal S; Domenger C; Kosmider O; Rabant M; Karras A; Duong Van Huyen JP
Kidney Int; 2023 Dec; 104(6):1206-1218. PubMed ID: 37769965
[TBL] [Abstract][Full Text] [Related]
33. Genetic mutations associated with blood count abnormalities in myeloid neoplasms.
Polprasert C; Kongkiatkamon S; Niparuck P; Rattanathammethee T; Wudhikarn K; Chuncharunee S; Kobbuaklee S; Suksusut A; Lanamtieng T; Lawasut P; Asawapanumas T; Bunworasate U; Rojnuckarin P
Hematology; 2022 Dec; 27(1):765-771. PubMed ID: 35766510
[TBL] [Abstract][Full Text] [Related]
34. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract][Full Text] [Related]
35. Advances in myelodysplastic/myeloproliferative neoplasms.
Prakash S; Arber DA; Bueso-Ramos C; Hasserjian RP; Orazi A
Virchows Arch; 2023 Jan; 482(1):69-83. PubMed ID: 36469102
[TBL] [Abstract][Full Text] [Related]
36. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
37. Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review.
Zhao M; Sun J; Liu S; Fan H; Fu Y; Tan Y; Gao S
J Int Med Res; 2021 May; 49(5):3000605211018426. PubMed ID: 34057843
[TBL] [Abstract][Full Text] [Related]
38. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
39. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
40. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]